As GLP-1s quiet the constant hum of hunger, are they a permanent pharmaceutical crutch, or can they create space to let us ...

Are there disparities in obesity prevalence and comorbidities based on sex and gender, and how should it inform treatment?

Among the 2,225 adults in the study, all under 60 years of age, 39.7% had obesity as defined only by higher BMI, while 39.1% ...

Obesity drug developers Structure Therapeutics (NASDAQ:GPCR) and Metsera (NASDAQ:MTSR) recorded sharp gains alongside Eli ...

Nearly all U.S. adults with obesity as diagnosed by BMI also have an elevated waist circumference or excess body fat, ...

As America’s obesity epidemic worsens and health gaps widen, one often overlooked factor stands out: access to gyms. Save for ...

The U.S. obesity rate is about 40%, according to a 2021-2023 survey of about 6,000 people. Nearly 1 in 10 of those surveyed reported severe obesity, the U.S. Centers for Disease Control and Prevention ...

Urgent action needed to tackle the rising obesity //burden . Obesity is more than a cosmetic concern - it's a major health challenge silently affecting millions around the world ...

Investors remain enthusiastic about the market for obesity drugs. The GLP-1 drugs Wegovy and Zepbound recorded sales of $8.4 billion and $4.9 billion respectively in 2024. Their climbing sales, along ...

WASHINGTON -- The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 ...